AS-101

DRUG4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Wyeth is now a wholly owned subsidiary of Pfizer

Conditions

HIV Infections

Phase 1

A Study of AS-101 in Patients With AIDS or AIDS Related Complex (ARC)

CompletedNCT00001006

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 1993-03-31Target: 30Updated: 2021-11-01

Unknown Phase

A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC Patients

CompletedNCT00002013

Wyeth is now a wholly owned subsidiary of PfizerHIV Infections

Updated: 2005-06-24

A Third-Party Blinded, Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced Disease

CompletedNCT00002033

Wyeth is now a wholly owned subsidiary of PfizerHIV Infections

Updated: 2005-06-24

An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients

CompletedNCT00002266

Wyeth is now a wholly owned subsidiary of PfizerHIV Infections

Updated: 2005-06-24

Related Papers

Comparison of spinal magnetic resonance imaging and classical clinical factors in predicting motor capacity in amyotrophic lateral sclerosis.

2023-04-277 citations